ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology

ErbB family members represent important biomarkers and drug targets for modern precision therapy. They have gained considerable importance as paradigms for oncoprotein addiction and personalized medicine. This review summarizes the current understanding of ErbB proteins in cell signalling and cancer and describes the molecular rationale of prominent cases of ErbB oncoprotein addiction in different cancer types. In addition, we have highlighted experimental technologies for the development of innovative cancer cell models that accurately predicted clinical ErbB drug efficacies. In the future, such cancer models might facilitate the identification and validation of physiologically relevant novel forms of oncoprotein and non-oncoprotein addiction or synthetic lethality. The identification of genotype-drug response relationships will further advance personalized oncology and improve drug efficacy in the clinic. Finally, we review the most important drugs targeting ErbB family members that are under investigation in clinical trials or that made their way already into clinical routine. Taken together, the functional characterization of ErbB oncoproteins have significantly increased our knowledge on predictive biomarkers, oncoprotein addiction and patient stratification and treatment.

• Publication year

  2017

• Venue

  Cancers

• Publication date

  2017-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3390/cancers9040033PMID 28417948PMCID 5406708
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting TAZ-Driven Human Breast Cancer by Inhibiting a SKP2-p27 Signaling Axis

  2018cited by this paper
• Targeting the EGFR T790M mutation in non-small-cell lung cancer

  2017cited by this paper
• Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers

  2017cited by this paper
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

  2017cited by this paper
• PI3K/Akt/mTOR Intracellular Pathway and Breast Cancer: Factors, Mechanism and Regulation.

  2017cited by this paper
• HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo‐ and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib

  2017cited by this paper
• High expression of CPNE3 predicts adverse prognosis in acute myeloid leukemia

  2017cited by this paper
• Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer

  2016cited by this paper
• An anti-ErbB2 fully human antibody circumvents trastuzumab resistance

  2016cited by this paper
• Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR‐Activating Mutation

  2016cited by this paper
• Role of targeted therapy in metastatic colorectal cancer

  2016cited by this paper
• Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer

  2016cited by this paper
• RAS isoforms and mutations in cancer at a glance

  2016cited by this paper
• Osimertinib making a breakthrough in lung cancer targeted therapy

  2016cited by this paper
• Uncoupling of EGFR–RAS signaling and nuclear localization of YBX1 in colorectal cancer

  2016cited by this paper
• Three-dimensional culture systems in cancer research: Focus on tumor spheroid model.

  2016cited by this paper
• The Panitumumab EGFR Complex Reveals a Binding Mechanism That Overcomes Cetuximab Induced Resistance

  2016cited by this paper
• Activating ERBB4 mutations in non-small cell lung cancer

  2016cited by this paper
• The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity

  2016cited by this paper
• Drugging the addict: non‐oncogene addiction as a target for cancer therapy

  2016cited by this paper
• Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer

  2016cited by this paper
• [MET receptor inhibition: Hope against resistance to targeted therapies?]

  2016cited by this paper
• Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms

  2016cited by this paper
• High-throughput imaging: Focusing in on drug discovery in 3D.

  2016cited by this paper
• The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

  2016cited by this paper
• PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells

  2016cited by this paper
• HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models

  2016cited by this paper
• Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds

  2016cited by this paper
• KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.

  2016cited by this paper
• Development of Organotypic Cancer Models for the Identification of Individualized Cancer Therapies

  2016cited by this paper
• Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus

  2016cited by this paper
• Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations

  2016cited by this paper
• TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun

  2016cited by this paper
• MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations

  2016cited by this paper
• The combinatorial approach of laser-captured microdissection and reverse transcription quantitative polymerase chain reaction accurately determines HER2 status in breast cancer

  2016influential reference
• Correlation of EGFR Del 19 with Fn14/JAK/STAT signaling molecules in non-small cell lung cancer.

  2016cited by this paper
• Past, Present, and Future of Targeting Ras for Cancer Therapies.

  2016cited by this paper
• Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer

  2016cited by this paper
• BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.

  2016cited by this paper
• Preclinical and clinical studies on afatinib in monotherapy and in combination regimens: Potential impact in colorectal cancer.

  2016cited by this paper
• AMPK and Cancer.

  2016cited by this paper
• Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis

  2015cited by this paper
• HBx sensitizes hepatocellular carcinoma cells to lapatinib by up-regulating ErbB3

  2015cited by this paper
• EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

  2015cited by this paper
• HER2-positive metastatic breast cancer: a changing scenario.

  2015cited by this paper
• Phase II Trial of Gefitinib in Combination with Bevacizumab as First-Line Therapy for Advanced Non–Small Cell Lung Cancer with Activating EGFR Gene Mutations: The Okayama Lung Cancer Study Group Trial 1001

  2015cited by this paper
• Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.

  2015cited by this paper
• ERBB4 is over-expressed in human colon cancer and enhances cellular transformation.

  2015cited by this paper
• Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer.

  2015cited by this paper
• RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.

  2015cited by this paper
• Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

  2015cited by this paper
• Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices

  2015cited by this paper
• Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance.

  2015cited by this paper
• The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.

  2015cited by this paper
• High EMT Signature Score of Invasive Non-Small Cell Lung Cancer (NSCLC) Cells Correlates with NFκB Driven Colony-Stimulating Factor 2 (CSF2/GM-CSF) Secretion by Neighboring Stromal Fibroblasts

  2015cited by this paper
• Phosphorylation of Glutathione S-Transferase P1 (GSTP1) by Epidermal Growth Factor Receptor (EGFR) Promotes Formation of the GSTP1-c-Jun N-terminal kinase (JNK) Complex and Suppresses JNK Downstream Signaling and Apoptosis in Brain Tumor Cells*

  2015cited by this paper
• Role of EGFR Monoclonal Antibodies in the Management of Non-small Cell Lung Cancer.

  2015cited by this paper
• Organoid models of human and mouse ductal pancreatic cancer.

  2015cited by this paper
• Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib‐resistant lung cancer growth

  2015cited by this paper
• Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models

  2015cited by this paper
• Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer

  2015cited by this paper
• Synchronized targeting of Notch and ERBB signaling suppresses melanoma tumor growth through inhibition of Notch1 and ERBB3

  2015cited by this paper
• MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells

  2015cited by this paper
• Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience

  2015cited by this paper
• KRAS Mutation as the Biomarker of Response to Chemotherapy and EGFR-TKIs in Patients With Advanced Non–Small Cell Lung Cancer: Clues For Its Potential Use in Second-Line Therapy Decision Making

  2015cited by this paper
• Treatment of HER2-positive metastatic breast cancer.

  2015cited by this paper
• Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure

  2015cited by this paper
• Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer

  2015cited by this paper
• HER3/ErbB3, an emerging cancer therapeutic target.

  2015cited by this paper
• Comparison of the 2007 and 2013 ASCO/CAP evaluation systems for HER2 amplification in breast cancer.

  2015cited by this paper
• Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity

  2015cited by this paper
• Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

  2015cited by this paper
• Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade

  2015cited by this paper
• Regulation of ERBB3/HER3 signaling in cancer

  2014cited by this paper
• Function-blocking ERBB3 antibody inhibits the adaptive response to RAF inhibitor.

  2014cited by this paper
• Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer

  2014influential reference
• IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor–stroma interaction

  2014cited by this paper
• Oncogene addiction: resetting the safety switch?

  2014cited by this paper
• ERBB4 mutation analysis: emerging molecular target for melanoma treatment.

  2014cited by this paper
• Modeling human carcinomas: physiologically relevant 3D models to improve anti-cancer drug development.

  2014cited by this paper
• Role of erbB3 receptors in cancer therapeutic resistance.

  2014cited by this paper
• 3-Dimensional Culture Systems for Anti-Cancer Compound Profiling and High-Throughput Screening Reveal Increases in EGFR Inhibitor-Mediated Cytotoxicity Compared to Monolayer Culture Systems

  2014cited by this paper
• The ErbB/HER family of protein-tyrosine kinases and cancer.

  2014influential reference
• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

  2014cited by this paper
• Three-Dimensional Lung Tumor Microenvironment Modulates Therapeutic Compound Responsiveness In Vitro – Implication for Drug Development

  2014cited by this paper
• One mouse, one patient paradigm: New avatars of personalized cancer therapy.

  2014influential reference
• ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.

  2014cited by this paper
• The Mysterious Ways of ErbB2/HER2 Trafficking

  2014cited by this paper
• Three‐dimensional models of cancer for pharmacology and cancer cell biology: Capturing tumor complexity in vitro/ex vivo

  2014cited by this paper
• HER2 aberrations in cancer: implications for therapy.

  2014cited by this paper
• Targeting MET Amplification as a New Oncogenic Driver

  2014cited by this paper
• A new tumour suppression mechanism by p27Kip1: EGFR down-regulation mediated by JNK/c-Jun pathway inhibition

  2014cited by this paper
• Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.

  2014cited by this paper
• Three-Dimensional In Vitro Co-Culture Model of Breast Tumor using Magnetic Levitation

  2014cited by this paper
• The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells

  2013cited by this paper
• A view on EGFR-targeted therapies from the oncogene-addiction perspective

  2013cited by this paper
• Aberrant IKKα and IKKβ cooperatively activate NF-κB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer

  2013cited by this paper
• The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies

  2013cited by this paper
• Translation of a Tumor Microenvironment Mimicking 3D Tumor Growth Co-culture Assay Platform to High-Content Screening

  2013cited by this paper
• Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers.

  2013cited by this paper

• Exploring the immunotoxicity and mechanisms of action of planktonic Microcystis and benthic Oscillatoria on juvenile filter-feeding fish

  2026cites this paper
• Targeting endothelial growth factor receptor in thyroid cancer: current concepts and future directions

  2025cites this paper
• Targeting C797S mutations and beyond in non-small cell lung cancer—a mini-review

  2024cites this paper
• Revealing the Potency of Growth Factors in Bovine Colostrum

  2024cites this paper
• ERBB2 Targeting Reveals a Significant Suppression of Tumorigenesis in Murine Endometrial Cancer with Pten Mutation

  2024cites this paper
• Production and functional analysis of a phage displayed scFv recombinant antibody targeting EGFR/HER2 dimerization domain.

  2024cites this paper
• Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro

  2024influential citation
• Afatinib in paediatric patients with recurrent/refractory ErbB-dysregulated tumours: Results of a phase I/expansion trial.

  2023cites this paper
• Matrix Selection for the Visualization of Small Molecules and Lipids in Brain Tumors Using Untargeted MALDI-TOF Mass Spectrometry Imaging

  2023cites this paper
• Navigating the Blood–Brain Barrier: Challenges and Therapeutic Strategies in Breast Cancer Brain Metastases

  2023cites this paper
• Pan-cancer chemoresistance-associated genes, affected pathways and potential therapeutic targets

  2023cites this paper
• Cranberry Polyphenols in Esophageal Cancer Inhibition: New Insights

  2022cites this paper
• Cascade Downregulation of the HER Family by a Dual‐Targeted Recombinant Protein–Drug Conjugate to Inhibit Tumor Growth and Metastasis

  2022cites this paper
• Bioimaging Nucleic-Acid Aptamers with Different Specificities in Human Glioblastoma Tissues Highlights Tumoral Heterogeneity

  2022cites this paper
• An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies

  2022cites this paper
• Network Pharmacology Integrated with Transcriptomics Analysis Reveals Ermiao Wan Alleviates Atopic Dermatitis via Suppressing MAPK and Activating the EGFR/AKT Signaling

  2022cites this paper
• Network Pharmacology Integrated with Transcriptomics Analysis Reveals Ermiao Wan Alleviates Atopic Dermatitis via Suppressing MAPK and Activating the EGFR/AKT Signaling

  2022cites this paper
• The Role of EREG/EGFR Pathway in Tumor Progression

  2021cites this paper
• Quantitative and bioinformatics integrated strategy to investigate the pharmacological mechanism of Ermiao Wan against eczema

  2021cites this paper
• A cell-based subtractive panning strategy for selection of conformation-specific single-chain variable-fragment (scFv) against dimerization domain of EGFR.

  2021cites this paper
• Comprehensive analysis of the ErbB receptor family in pediatric nervous system tumors and rhabdomyosarcoma

  2021cites this paper
• Self-Assembled Dual-Targeted Epirubicin-Hybrid Polydopamine Nanoparticles for Combined Chemo-Photothermal Therapy of Triple-Negative Breast Cancer

  2020cites this paper
• Synergism of Proneurogenic miRNAs Provides a More Effective Strategy to Target Glioma Stem Cells

  2020cites this paper
• Promoter Methylation of Selected Genes in Non-Small-Cell Lung Cancer Patients and Cell Lines

  2020cites this paper
• ErbB1 and ErbB2 overexpression in patients with sinonasal inverted papilloma and inverted papilloma with squamous cell carcinoma in China

  2019influential citation
• Preparation and characterization of humanized nanobodies targeting the dimer interface of epidermal growth factor receptor (EGFR).

  2019cites this paper
• RNA Aptamers Targeting Integrin α5β1 as Probes for Cyto- and Histofluorescence in Glioblastoma

  2019cites this paper
• Targeting TAZ-Driven Human Breast Cancer by Inhibiting a SKP2-p27 Signaling Axis

  2018cites this paper
• The Neuroprotective Effect of Ethanol Intoxication in Traumatic Brain Injury Is Associated with the Suppression of ErbB Signaling in Parvalbumin-Positive Interneurons

  2018cites this paper
• [Research advances in the role of aptamers in the diagnosis and targeted therapy of pediatric cancer].

  2018cites this paper
• Selection of Nucleic Acid Aptamers Targeting Tumor Cell-Surface Protein Biomarkers

  2017cites this paper
• High expression of CPNE3 predicts adverse prognosis in acute myeloid leukemia

  2017cites this paper
• Identification of Differentially Expressed Genes between Original Breast Cancer and Xenograft Using Machine Learning Algorithms

  year unknowncites this paper